Rare disease group Swedish Orphan Biovitrum (Sobi) says it has gained NHS England reimbursement for Ravicti for long-term management of urea-cycle disorders (UCDs) in adults and children.
The Scottish Medicines Consortium has approved funding for four newly licensed medicines, expanding NHS treatments options in Scotland for ovarian cancer, lung cancer, urea cycle disorders and acute hereditary angioedema.